Excellent response to the clinical treatment of tophaceous gout.
Gout continues to be a health problem around the world, and the treatment may turn into a real challenge when the patient presents a certain degree of chronic renal failure (CRF). We discuss a case of tophaceous gout in a 68-year-old male patient without urolithiasis and with uric acid (UA) underexcretion and CRF (creatinine clearance of 42 ml/min). Uricosuric treatment with benzbromarone and urinary alkalinization was administered, and acute gouty attacks improved substantially. Subsequently, allopurinol was added to the treatment to accelerate tophi reduction in the hands, feet, elbows and knees. After 30 months of treatment, serum UA declined from 10 to 3.2 mg/dl. Urinary UA excretion of 0.44 g/24 h in the baseline rose to 0.85 g/24 h, returning to the baseline value after 30 months. UA clearance tripled, rising from 3.05 ml/min before treatment to 9.48 ml/min, and remained at this level. It is worth stressing that even in cases of severe tophaceous gout, the response to clinical treatment may be satisfactory with substantial reduction of tophi and full acute gouty attack remission even in patients presenting a certain degree of CRF.
Caldas
Cezar Augusto Muniz
CA
Discipline of Rheumatology of the São Paulo University Medical School, Brazil. cezar_caldas@yahoo.com.br
Fuller
Ricardo
R
D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D001553:Benzbromarone / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate; D006073:Gout / Q000150:complications / Q000188:drug therapy*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood / Q000378:metabolism / Q000652:urine*; D014528:Uricosuric Agents / Q000627:therapeutic use*
D006074:Gout Suppressants; D014528:Uricosuric Agents; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol